Amfetamine extended-release (liquid suspension)- Neos Therapeutics

Drug Profile

Amfetamine extended-release (liquid suspension)- Neos Therapeutics

Alternative Names: Adzenys ER; Amphetamine extended-release oral suspension; Amphetamine XR-liquid suspension; Amphetamine XR-suspension - Neos Therapeutics; Extended release amphetamine liquid suspension - Neos Therapeutics; NT-0201

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neos Therapeutics
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Attention-deficit hyperactivity disorder

Most Recent Events

  • 15 Sep 2017 Registered for Attention-deficit hyperactivity disorder in USA (PO)
  • 19 May 2017 Chemical structure information added
  • 15 Mar 2017 Neos Therapeutics has patent protection for methods of preparation of amfetamine extended release in USA until 2025, 2029 and 2031
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top